rocbrutinib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a combination regimen comprising **rocbrutinib** (a Bruton’s tyrosine kinase inhibitor), **rituximab** (an anti-CD20 monoclonal antibody), **cyclophosphamide** (an alkylating agent), **doxorubicin** (an anthracycline topoisomerase II inhibitor), **vincristine** (a vinca alkaloid microtubule inhibitor), and **prednisone** (a synthetic glucocorticoid). Such a regimen would provide both targeted immunotherapy (via BTK and CD20 inhibition) and broad cytotoxic effects (via alkylation, topoisomerase inhibition, and microtubule disruption), along with immunosuppression (via corticosteroid), aimed at treating aggressive hematological malignancies or highly refractory autoimmune disease. The specific combination of all six drugs is not an established, approved protocol and is not documented in standard references as a defined combination regimen, but most of the drugs are used either together or in close sequence for lymphoma, vasculitis, or related indications[1][2].